Top Stories
The startup plans to extend its model of pairing prescription medicines with therapeutic software to other disease areas.
The Chinese biotech is developing a small-molecule eye drop for retinal diseases, as well as a second-generation menin inhibitor for leukaemia.
Gilead is using Nucleai AI's Tissue Intelligence platform to better understand why some patients respond to antibody-drug conjugates and others do not.
The companies will also study wearable, lab and survey data, with the findings feeding into future Google Health coaching and Lingo features.
Financing will support training of foundation models and expansion of the Lab-in-the-Loop engine.
Conference News
SAN FRANCISCO--(BUSINESS WIRE)-- Astro Health Inc., a San Francisco-based artificial intelligence digital health company, today announced that its first peer-reviewed research from its clinical study ...
12 Aug 2026Experts' discussions during the ESMO Gastrointestinal Cancers Congress 2026 explored how AI is moving beyond image recognition to support surgery, pathology and image-guided intervention.Th...
University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to ...
Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...
